News

Law

Asset Management

Investment Banking

Wealth

Hedge Funds

People

Newsletters

Events

Lists

Novartis calls in Lazard and CSFB for Aventis merger talks

Credit Suisse First Boston and Lazard are advising Novartis, the Swiss pharmaceuticals company, which is understood to be putting the finishing touches to a "white knight" bid for Aventis, the Franco-German pharmaceuticals company.

According to banking sources, Novartis could launch an offer next week, in order to scupper the existing €46bn hostile bid for Aventis by Sanofi-Synthélabo, the French pharmaceuticals firm.

WSJ Logo